BLOG

Adipose Stem Cell Therapy in Osaka: Risks and Questions to Ask

Published 2026.10.13 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

Anyone considering adipose-derived stem cell therapy in Japan will sooner or later ask the same question: what could go wrong? A treatment that uses your own cells can sound gentle, but any medical procedure carries risks, and a good consultation begins with an honest discussion of them. This article explains the kinds of risks patients commonly ask about and the questions worth bringing to a doctor at Grand Green Osaka Umekita Clinic or any other clinic you are comparing.

The short answer: ask about risks before benefits

Adipose-derived stem cell therapy is a self-pay (non-insured) regenerative treatment. It is not a guaranteed solution, and responses differ from person to person. The most useful way to prepare is to ask about risks, side effects, and limits of the evidence first, and only then consider possible benefits. The information here is general education and cannot replace an examination. Whether the treatment suits you, and what it would cost, must be confirmed with a physician.

What the treatment involves, and where risks can arise

In this treatment, a very small amount of fat tissue is collected from the patient under local anesthesia. Mesenchymal stem cells in that tissue are cultured and expanded at a specialized facility, and the cells are later returned to the body by intravenous (IV) infusion. Both the fat collection and the infusion are done on an outpatient basis.

Each step has its own points to understand:

Fat collection: a small incision is made, so bruising, soreness, bleeding, infection, or a reaction to local anesthesia are possible in principle.
Cell culture: cells are grown outside the body, so sterility and quality control at the processing facility matter.
IV infusion: as with any infusion, there can be discomfort at the needle site, and some patients may experience a temporary reaction such as a mild fever or fatigue.
Individual factors: medical history, current medications, allergies, and existing conditions can change how a person should be assessed.

Using your own cells, known as autologous treatment, is generally considered to lower the risk of rejection compared with donor cells. However, lower risk does not mean no risk, and you should not read it as a promise of safety.

How Japanese regulation relates to safety

In Japan, this type of treatment is provided under the Act on the Safety of Regenerative Medicine. Under this law, a clinic must submit a regenerative medicine provision plan that has been reviewed by a certified committee, and the cell processing must take place at a facility that has been notified to the authorities. These rules exist to set a framework for safety management and oversight.

It is important to understand what the framework does and does not mean. It means that the treatment is provided within a structured system with documented procedures. It does not mean that a treatment has been approved by the government as an insured therapy for a specific disease, and it does not guarantee any particular result. Patients are encouraged to ask the clinic to explain which plan covers their treatment and how adverse events are handled.

Questions to bring to your consultation

A written list can make a short consultation more productive, especially if you are a visitor from overseas and the appointment is time-limited. Consider asking the following:

What are the known and possible side effects of fat collection and of IV infusion?
What is the evidence for treatment in my situation, and what are the limits of that evidence?
Is my condition suitable for this treatment, and are there standard treatments I should consider first or continue?
How many visits are required, how long does the culture period take, and what is the total cost, including follow-up?
What happens if I have a problem after I return home?
Will the doctor review my current medications and medical records before proceeding?

A responsible clinic will welcome these questions. If an answer sounds like a guarantee, or if the risks are not discussed at all, that is a reason to pause and ask for clarification.

Considering treatment in Osaka as an international patient

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka and offers an information page for international patients, so you can learn about the flow of treatment in your own language before you arrive. Because treatment involves a collection visit, a culture period, and an infusion visit, it is worth thinking about your travel schedule, your ability to return for follow-up, and how you would reach a doctor if you had a concern after going home.

Please also bring your medical history, a list of current medicines, and any recent test results. Stem cell therapy is not a substitute for standard medical care, and it should not replace treatment your own doctor has recommended without a discussion with that doctor.

Summary

Adipose-derived stem cell therapy is a self-pay regenerative option provided in Japan under the Act on the Safety of Regenerative Medicine. Risks exist at the stages of fat collection, cell culture, and infusion, and the evidence has limits. Costs, risks, side effects, and suitability should always be confirmed through a consultation with a physician. Going in with clear questions helps you decide calmly whether this treatment is right for you.

Questions Before Treatment

Ask about risksCollection, culture, infusion
Know the frameworkRegenerative medicine act
Self-pay treatmentConfirm costs in advance
Doctor consultationSuitability is assessed

This figure is a conceptual diagram summarizing the article

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›